What Selank is. And where it comes from
Selank is a synthetic heptapeptide based on tuftsin. A naturally occurring tetrapeptide fragment of immunoglobulin G (IgG) that plays a role in immune regulation. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same group that created Semax. While Semax targets cognition, Selank was designed as an anxiolytic.
Like Semax, it is administered as a nasal spray with a Pro-Gly-Pro C-terminal extension for enzymatic stability. It was approved in Russia in the mid-2000s as a prescription anxiolytic. An anti-anxiety agent without the sedation or dependence of benzodiazepines.
Selank is the anxiolytic counterpart to Semax. Same institution, same delivery method, different target. Where Semax aims at attention and memory, Selank aims at anxiety and stress resilience, without the sedation and dependence issues of benzodiazepines.
Mechanism, in plain English
The published literature identifies several neurological pathways influenced by Selank. These are reported in both animal models and human studies from Russian research groups.
Want all 23 cognitive enhancement compounds in one place?
The Peptexa Cognitive Enhancement guide covers every compound in this category, mechanism, evidence level, and regulatory status for each.
What the human evidence shows
Selank has published human clinical data, primarily from Russian research groups. Studies report anxiolytic effects comparable to benzodiazepines but without the sedation, dependence, or cognitive impairment typically associated with that drug class. Clinical applications studied include generalized anxiety disorder and adjustment disorders.
Additional human studies report effects on cognitive function under stress, immune modulation (consistent with its tuftsin origin), and gene expression changes related to neurotransmitter systems. The most-cited reference is Zozulya et al. (2008).
The evidence level is ★★★☆☆, preliminary human evidence. Human data exists and is meaningful, but independent Western RCT replication is limited. The signal is real; the verification gap is about study design standards, not absence of data.
Selank may be the closest thing to a benzodiazepine alternative in the peptide world. At least based on the Russian clinical data. The question is whether Western-standard trials would replicate those findings.
Regulatory status
Selank is not FDA-approved in the United States for any indication. It is classified as a research compound in the US.
In Russia, Selank has been approved since the mid-2000s as a prescription anxiolytic nasal spray. It is listed in the Russian State Register of Medicines. Last reviewed 2026-08-19.
Common synonyms researchers use
Selank · TP-7 · Tuftsin analog · Thr-Lys-Pro-Arg-Pro-Gly-Pro. Also referenced as "anxiolytic peptide Selank" in Russian medical literature.
Safety & adverse-event landscape
In the published Russian clinical literature, Selank administered intranasally has a favorable safety profile. Unlike benzodiazepines, it does not appear to cause sedation, cognitive impairment, or dependence in published studies. Side effects are described as rare and mild, primarily nasal irritation.
Long-term safety data from Western-standard monitoring is not available. As a compound that modulates GABAergic and serotonergic systems, theoretical interactions with psychiatric medications (benzodiazepines, SSRIs, anxiolytics) should be considered. Consult your provider.
Peptexa is an educational resource. We do not provide dosing guidance, sourcing recommendations, or protocol advice. Always consult a qualified healthcare provider before any decision involving a peptide or therapeutic compound.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Cognitive Enhancement reference
23 compounds. Mechanism, evidence level, and regulatory status for every one.
Get the Cognitive Enhancement Guide →